Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy

被引：122

作者：

Hakki, Morgan

Staab, Janet F.

Marr, Meren A.

机构：

[1] Univ Washington, Fred Hutchinson Canc Res Ctr, Program Infect Dis, Seattle, WA 98109 USA

[2] Univ Washington, Div Allergy & Infect Dis, Seattle, WA 98109 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2006年 / 50卷 / 07期

关键词：

D O I：

10.1128/AAC.00148-06

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Clinical failure associated with reduced susceptibility to caspofungin has been described in Candida albicans and C parapsilosis. We report a case of Candida krusei infection that progressed despite caspofungin therapy. Reduced microbial susceptibility to all three echinocandins (caspofungin, anidulafungin, and micafungin) was noted but was not associated with mutations in FKS1.

引用

页码：2522 / 2524

页数：3

共 11 条

[1] Sensititre YeastOne caspofungin susceptibility testing of Candida clinical isolates:: Correlation with results of NCCLS M27-A2 multicenter study [J].

Cantón, E ;

Pemán, J ;

Gobernado, M ;

Alvarez, E ;

Baquero, F ;

Cisterna, R ;

Gil, J ;

Martín-Mazuelos, E ;

Rubio, C ;

Sánchez-Sousa, A ;

Serrano, C .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (04) :1604-1607

[2] Hsp90 potentiates the rapid evotution of new traits: Drug resistance in diverse fungi [J].

Cowen, LE ;

Lindquist, S .

SCIENCE, 2005, 309 (5744) :2185-2189

[3]

Deresinski SC, 2003, CLIN INFECT DIS, V36, P1445, DOI 10.1086/375080

[4] Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors [J].

Douglas, CM ;

DIppolito, JA ;

Shei, GJ ;

Meinz, M ;

Onishi, J ;

Marrinan, JA ;

Li, W ;

Abruzzo, GK ;

Flattery, A ;

Bartizal, K ;

Mitchell, A ;

Kurtz, MB .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) :2471-2479

[5] Caspofungin resistance in Candida albicans:: Correlating clinical outcome with laboratory susceptibility testing of three is genic isolates serially obtained from a patient with progressive candida esophagitis [J].

Hernandez, S ;

López-Ribot, JL ;

Najvar, LK ;

McCarthy, DI ;

Bocanegra, R ;

Graybill, JR .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (04) :1382-1383

[6] Multiechinocandin- and multiazole-resistant Candida parapsilosis solates serially obtained during therapy for prosthetic valve endocarditis [J].

Moudgal, V ;

Little, T ;

Boikov, D ;

Vazquez, JA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (02) :767-769

[7]

National Committee for Clinical Laboratory Standards, 2002, M27A2 NAT COMM CLIN

[8] Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species [J].

Odds, FC ;

Motyl, M ;

Andrade, R ;

Bille, J ;

Cantón, E ;

Cuenca-Estrella, M ;

Davidson, A ;

Durussel, C ;

Ellis, D ;

Foraker, E ;

Fothergill, AW ;

Ghannoum, MA ;

Giacobbe, RA ;

Gobernado, M ;

Handke, R ;

Laverdière, M ;

Lee-Yang, W ;

Merz, WG ;

Ostrosky-Zeichner, L ;

Pemán, J ;

Perea, S ;

Perfect, JR ;

Pfaller, MA ;

Proia, L ;

Rex, JH ;

Rinaldi, MG ;

Rodriguez-Tudela, JL ;

Schell, WA ;

Shields, C ;

Sutton, DA ;

Verweij, PE ;

Warnock, DW .

JOURNAL OF CLINICAL MICROBIOLOGY, 2004, 42 (08) :3475-3482

[9] Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp isolates [J].

Park, S ;

Kelly, R ;

Kahn, JN ;

Robles, J ;

Hsu, MJ ;

Li, W ;

Vyas, V ;

Fan, H ;

Abruzzo, G ;

Flattery, A ;

Gill, C ;

Chrebet, G ;

Parent, SA ;

Kurtz, A ;

Teppler, H ;

Douglas, CA ;

Perlin, DS .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (08) :3264-3273

[10] Comparison of PCR- and HinfI restriction endonuclease-based methods for typing of Candida krusei isolates [J].

Sancak, B ;

Rex, JH ;

Chen, E ;

Marr, K .

JOURNAL OF CLINICAL MICROBIOLOGY, 2004, 42 (12) :5889-5891

← 1 2 →